Ascendis Pharma A/S
ASND
Classificação em ações
#1455
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Preço da ação
$238.30
Última sincronização: 2026-10-21
Valor de mercado
$14.86B
Variação (1 dia)
1.69%
Variação (1 ano)
17.56%
País
DK
Negociar Ascendis Pharma A/S (ASND)
Categoria
Healthcare
Histórico de preços das ações de Ascendis Pharma A/S (ASND)
Preço de fecho mais alto: $228.08 em 2026-10-01
Preço de fecho mais baixo: $19.55 em 2015-01-01
Preço de fecho mais baixo: $19.55 em 2015-01-01
Histórico de preços das ações da Ascendis Pharma A/S de 2015 a 2026
Desempenho anual do preço das ações
| Ano | Desempenho |
|---|---|
| 2026 (TTM) | 11.08% |
| 2025 | 53.71% |
| 2024 | 15.66% |
| 2023 | -2.60% |
| 2022 | -12.93% |
| 2021 | -20.35% |
| 2020 | 42.79% |
| 2019 | 94.20% |
| 2018 | 63.66% |
| 2017 | 87.65% |
| 2016 | 15.96% |
| 2015 | 0.00% |
Preço das ações de empresas similares ou concorrentes
| Empresa | Preço da ação | Variação 1a% | País |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
